Home / Stocks / RCDTF

RCDTF (Pharmaceuticals) Stock Valuation & Fair Value Quality business with a solid forward outlook

RCDTF (Pharmaceuticals) trades at a blended P/E of 16.6, about 7% below its historical normal valuation, with a forward growth estimate of 12.4% and a PEG of 1.34. Analysts' one-year estimates have been hit 64% of the time.

DATA AS OF 2026-09-21
Blended P/E
16.6
Normal P/E
17.9
PEG
1.34
Fwd growth
12.4%
Div yield
2.5%
RSI (14)
50.0
Neutral

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 16.6 to 16.6 between 2026-09-19 and 2026-09-21, against a normal P/E of 17.9, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 16.6, Quality business with a solid forward outlook (recalculated)2026-09-21: P/E 16.6, Quality business with a solid forward outlook17.017.5Sep 19Sep 20Sep 21Normal P/E 17.9
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 16.6-7%Quality business with a solid forward outlook
2026-09-21P/E 16.6-7%Quality business with a solid forward outlook ← now

Frequently asked questions

Is RCDTF overvalued?

At a blended P/E of 16.6 versus its historical normal P/E of 17.9, RCDTF trades about 7% below its typical valuation, with a PEG of 1.34 on 12.4% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is RCDTF's fair value and PEG?

RCDTF trades at a blended P/E of 16.6 against a historical normal P/E of 17.9, a PEG of 1.34, and a forward growth estimate of 12.4%.

Has tickerseer's rating of RCDTF changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-09-19.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track RCDTF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.